Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 07, 2024

Efficacy of Neratinib Plus Ado-Trastuzumab Emtansine for Pretreated and Untreated HER2+ Breast Cancer Brain Metastases

Annals of Oncology

 

Additional Info

Annals of Oncology
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022
Ann. Oncol 2024 Nov 01;35(11)993-1002, RA Freedman, HM Heiling, T Li, D Trapani, N Tayob, KL Smith, R Davis, AM Pereslete, MK DeMeo, C Cotter, WY Chen, HA Parsons, CA Santa-Maria, C Van Poznak, B Moy, AM Brufsky, ME Melisko, CC O'Sullivan, N Ashai, Y Rauf, JR Nangia, RT Burns, J Savoie, AC Wolff, EP Winer, MF Rimawi, IE Krop, NU Lin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading